SCOUT-HCM demonstrated the superiority of Camzyos on the primary endpoint and multiple secondary endpointsThe overall safety results in this study were consistent with the established safety profile ...
The U.S. Food and Drug Administration has approved Myqorzo (aficamten) for the treatment of adults with symptomatic ...
Review clinical classifications, diagnostic procedures, and management strategies for cardiomyopathy and heart failure in this comprehensive overview.
Background Ebstein’s anomaly (EA) exhibits significant anatomical and clinical heterogeneity, warranting a systematic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback